NON-INVASIVE FUNCTIONAL COMPANION ASSAYS FOR ONCOGENE TARGETED THERAPY FOR BRAIN CANCER

摘要

The present disclosure relates to methods for determining the metabolic responder status of a subject having glioblastoma (GBM) and adjusting the course of treatment accordingly. The disclosure further relates to methods of treating GBM and other EGFR- mediated cancers. The disclosure further relates to methods of identifying effective treatments for subjects having GBM.